2025 ICD-10-CM code D59.2
Drug-induced nonautoimmune hemolytic anemia. This occurs when certain drug reactions damage red blood cells, usually destroying cell membranes.
Medical necessity is established by the presence of signs, symptoms, and laboratory findings consistent with drug-induced nonautoimmune hemolytic anemia.The documentation should support the diagnosis and demonstrate the need for interventions such as discontinuation of the causative medication, corticosteroid therapy, or blood transfusions.
Physicians diagnose this condition based on medical history, physical exam, and symptoms, which may include weakness, fatigue, shortness of breath, rapid heart rate, dark urine, yellowing of the skin and eyes (jaundice), and enlarged spleen and liver.Lab tests like complete blood count (CBC), reticulocyte count, hemoglobin, bilirubin, and Coombs test are used to confirm the diagnosis. Treatment typically involves stopping the offending medication. Corticosteroids or blood transfusions may be necessary in severe cases.
- Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism (D50-D89)
- Hemolytic anemias (D55-D59)
In simple words: This type of anemia happens when some medicines damage your red blood cells.This makes them break down earlier than they should.It's different from other types of anemia because it’s not caused by your body’s immune system attacking its own cells. Instead, the medicines themselves directly harm the red blood cells.
Drug-induced nonautoimmune hemolytic anemia is a condition characterized by the premature destruction of red blood cells (hemolysis) due to the adverse effects of certain medications.This destruction is not mediated by the body's own immune system (nonautoimmune), differentiating it from other forms of drug-induced hemolytic anemia. The drugs damage the red blood cell membranes, leading to their destruction. Examples of drugs that can cause this condition include primaquine, dapsone, and sulfasalazine.
Example 1: A patient taking primaquine for malaria develops fatigue, shortness of breath, and dark urine.Blood tests reveal anemia and a positive Coombs test. The primaquine is discontinued, and the patient's condition improves., A patient with rheumatoid arthritis being treated with dapsone experiences increasing fatigue and pallor.Lab tests show a decreased hemoglobin and hematocrit, and the dapsone is identified as the cause of the hemolytic anemia., A patient with inflammatory bowel disease taking sulfasalazine presents with jaundice and an enlarged spleen. Diagnostic tests reveal drug-induced nonautoimmune hemolytic anemia. Sulfasalazine is stopped, and alternative treatment is initiated.
Documentation should include the patient's medication history, signs and symptoms, lab test results (CBC, reticulocyte count, hemoglobin, bilirubin, Coombs test), and the causal relationship between the medication and the hemolytic anemia. The type of drug-induced hemolytic anemia (nonautoimmune in this case) should be clearly specified.
- Specialties:Hematology, Internal Medicine, Family Medicine
- Place of Service:Inpatient Hospital, Outpatient Hospital, Office, Independent Clinic